A Randomized, Double‐Blind, Double‐Dummy, Multicenter Trial of Voriconazole and Fluconazole in the Treatment of Esophageal Candidiasis in Immunocompromised Patients

Ally, R., Schürmann, D., Kreisel, W., Carosi, G., Aguirrebengoa, K., Dupont, B., Hodges, M., Troke, P. +2 more·2001·Clinical Infectious Diseases
DOI 10.1086/322653

Cited by (331)

Items 101–200 of 331

  1. Fatal Type 3 Adenoviral Pneumonia in Immunocompetent Adult Identical Twins
    Jason H. Barker, James P. Luby, A. S. Dalley, W. M. Bartek, Dennis K. Burns, Dean D. Erdman · 2003 · Clinical Infectious Diseases
  2. Progressive Multifocal Leukoencephalopathy Following Heightened Immunosuppression After Lung Transplant
    Jesse J. Waggoner, Tereza Martinu, Scott M. Palmer · 2009 · The Journal of Heart and Lung Transplantation
  3. Oral Voriconazole Versus Intravenous Low Dose Amphotericin B for Primary Antifungal Prophylaxis in Pediatric Acute Leukemia Induction
    Sushil Mandhaniya, Chetanya Swaroop, Sanjay Prayagraj Thulkar, Sreenivas Vishnubhatla, Sushil Kumar Kabra, Immaculata Xess, Sameer Bakhshi · 2011 · Journal of Pediatric Hematology/Oncology
  4. A comparative study of fungicidal activities of voriconazole and amphotericin B against hyphae of Aspergillus fumigatus
    Suganthini Krishnan, Elias K. Manavathu, Pranatharthi Haran Chandrasekar · 2005 · Journal of Antimicrobial Chemotherapy
  5. A Phase 2, Randomized, Double-Blind, Multicenter Trial To Evaluate the Safety and Efficacy of Three Dosing Regimens of Isavuconazole Compared with Fluconazole in Patients with Uncomplicated Esophageal Candidiasis
    J. Viljoen, Nkechi E. Azie, Anne-Hortense Schmitt-Hoffmann, Mahmoud Afif Ghannoum · 2015 · Antimicrobial Agents and Chemotherapy
  6. Invasive Oesophageal Candidiasis
    José A. Vázquez · 2003 · Drugs
  7. Improved outcomes associated with advances in therapy for invasive fungal infections in immunocompromised hosts
    Sarah C. Metcalf, David Harold Dockrell · 2007 · Journal of Infection
  8. Antifungal use in HIV infection
    Eleftherios E Mylonakis, Francisco M. Marty · 2002 · Expert Opinion on Pharmacotherapy
  9. Meta-analysis of the safety of voriconazole in definitive, empirical, and prophylactic therapies for invasive fungal infections
    Yuanming Xing, Lu Chen, Yan Feng, Yan Zhou, Yajing Zhai, Jun Lü · 2017 · BMC Infectious Diseases
  10. Pharmacokinetic Modeling of Voriconazole To Develop an Alternative Dosing Regimen in Children
    Silke Gastine, Thomas Lehrnbecher, Carsten Müller, Fedja Farowski, Peter Bader, Judith Ullmann-Moskovits, Oliver A. Cornely, Andreas H. Groll, Georg Hempel · 2017 · Antimicrobial Agents and Chemotherapy
  11. Measurement of voriconazole in serum and plasma
    Loralie J. Langman, Felix Boakye‐Agyeman · 2007 · Clinical Biochemistry
  12. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies
    Elizabeth M. Johnson, Ana Espinel‐Ingroff, Adrien Székely, Hans P. Hockey, Peter F. Troke · 2008 · International Journal of Antimicrobial Agents
  13. Voriconazole: review of a broad spectrum triazole antifungal agent
    Grzegorz Kofla, Markus Ruhnke · 2005 · Expert Opinion on Pharmacotherapy
  14. Voriconazole versus amphotericin B in cancer patients with neutropenia
    Karsten Juhl Jørgensen, Peter Christian Gøtzsche, Helle Krogh Johansen · 2006 · Cochrane Database of Systematic Reviews
  15. Voriconazole hepatotoxicity in severe liver dysfunction
    Pablo Solís‐Muñoz, Juan Carlos López, William E. Bernal, Christopher Willars, Ana Verma, Michael A. Heneghan, Julia Alexis Wendon, Georg M. Auzinger · 2012 · Journal of Infection
  16. Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia
    Karsten Juhl Jørgensen, Peter Christian Gøtzsche, Christina Schjellerup Eickhardt‐Dalbøge, Helle Krogh Johansen · 2014 · Cochrane Database of Systematic Reviews
  17. Therapy and prophylaxis of opportunistic infections in HIV-infected patients: a guideline by the German and Austrian AIDS societies (DAIG/ÖAG) (AWMF 055/066)
    Jan Thoden, Anja Verena Potthoff, Johannes Richard Bogner, Norbert Hermann Brockmeyer, S. Esser, Katharina Grabmeier‐Pfistershammer, Bernhard J. Haas, Katrin Hahn, Georg Härter, M. Hartmann et al. · 2013 · Infection
  18. Antifungal activity of amphotericin B and voriconazole against the biofilms and biofilm-dispersed cells of Candida albicans employing a newly developed in vitro pharmacokinetic model
    Mohamed El-Azizi, Noha Samir Farag, Nancy Misri Khardori · 2015 · Annals of Clinical Microbiology and Antimicrobials
  19. Management of systemic fungal infections: alternatives to itraconazole
    Raoul Herbrecht, Yasmine Nivoix, Cécile Fohrer, Shanti Natarajan‐Amé, V. Letscher‐Bru · 2005 · Journal of Antimicrobial Chemotherapy
  20. Voriconazole for serious fungal infections
    Philip Gothard, Thomas Richard Rogers · 2004 · International Journal of Clinical Practice
  21. Update on antifungal treatment of invasive Candida and Aspergillus infections
    Georg Maschmeyer, Markus Ruhnke · 2004 · Mycoses
  22. The Gastrointestinal Complications of Oncologic Therapy
    Mehnaz Azra Shafi, Robert S. Bresalier · 2010 · Gastroenterology Clinics of North America
  23. Mucosal and Systemic Fungal Infections in Patients with AIDS
    Markus Ruhnke · 2004 · Drugs
  24. Actividad in vitro del voriconazol, fluconazol, itraconazol y anfotericina B contra levaduras no Candida albicans
    D. Swinne, Mirjam Watelle, NICOLE NOLARD · 2005 · Revista Iberoamericana de Micología
  25. Voriconazole: a broad-spectrum triazole for the treatment of invasive fungal infections
    Jane A. Cecil, Richard P. Wenzel · 2009 · Expert Review of Hematology
  26. Pharmacokinetic interactions of efavirenz and voriconazole in healthy volunteers
    Bharat D. Damle, Robert R. LaBadie, Penelope H. Crownover, Paul Glue · 2008 · British Journal of Clinical Pharmacology
  27. Diagnose und Therapie von Pilzinfektionen und der Pneumozystis-Pneumonie bei Kindern und Jugendlichen mit neoplastischen Erkrankungen
    Andreas H. Groll, Joerg Ritter · 2005 · Klinische Pädiatrie
  28. Invasive candidiasis: update on current pharmacotherapy options and future perspectives
    Athanasios Tragiannidis, Christos Tsoulas, Kornelius Kerl, Andreas H. Groll · 2013 · Expert Opinion on Pharmacotherapy
  29. Voriconazole-induced periostitis in two post-transplant patients
    Matthew D. Bucknor, Andrew Gross, Thomas M. Link · 2013 · Journal of Radiology Case Reports
  30. Gastrointestinal infections in the immunocompromised host
    Lori E. Fantry · 2000 · Current Opinion in Gastroenterology
  31. New and Investigational Triazole Agents for the Treatment of Invasive Fungal Infections
    A. De Sarro, Erminia La Camera, Maria Teresa Fera · 2008 · Journal of Chemotherapy
  32. New agents for invasive mycoses in children
    Charalampos Antachopoulos, Thomas J. Walsh · 2005 · Current Opinion in Pediatrics
  33. Diagnostik und Therapie der Keratomykose
    W. Behrens‐Baumann · 2009 · Der Ophthalmologe
  34. Pediatric antifungal agents
    Michael Cohen‐Wolkowiez, Cassandra Moran, Daniel K. Benjamin, Phillip Brian Smith · 2009 · Current Opinion in Infectious Diseases
  35. Recent advances in antifungal pharmacotherapy for invasive fungal infections
    Jason C Gallagher, Conan MacDougall, Elizabeth S. Dodds Ashley, John R. Perfect · 2004 · Expert Review of Anti-infective Therapy
  36. Triazole Use in the Nursery: Fluconazole, Voriconazole, Posaconazole, and Ravuconazole
    Kevin Watt, Paolo Manzoni, Michael Cohen‐Wolkowiez, Stefano Rizzollo, Elena Boano, Évelyne Jacqz-Aigrain, Daniel K. Benjamin · 2013 · Current Drug Metabolism
  37. New agents for the treatment of systemic fungal infections – current status
    John H. Rex, Sevtap Arıkan · 2002 · Expert Opinion on Emerging Drugs
  38. Systemic Antifungal Agents: An Update of Established and New Therapies
    Daniel S. Loo · 2006 · Advances in Dermatology
  39. Pharmacotherapy of yeast infections
    Alicia Gómez‐López, Óscar Zaragoza, Juan L. Rodrı́guez-Tudela, Manuel Cuenca‐Estrella · 2008 · Expert Opinion on Pharmacotherapy
  40. Gastrointestinal infections in immunocompromised hosts
    Graeme N. Forrest · 2003 · Current Opinion in Gastroenterology
  41. Clinical safety and tolerability issues in use of triazole derivatives in management of fungal infections
    Dennis Neofytos · 2010 · Drug Healthcare and Patient Safety
  42. Clinical Pharmacology of Anti-Infective Drugs
    Kelly Cant Wade, Daniel K. Benjamin · 2010 · Elsevier eBooks
  43. Update on antifungal therapy
    Amy M. Grooters, Joseph Taboada · 2003 · Veterinary Clinics of North America Small Animal Practice
  44. Voriconazole-induced periostitis: a new rheumatic disorder
    Marwan Hmoud Adwan · 2016 · Clinical Rheumatology
  45. Clinical Use and Tolerability of Voriconazole in the Treatment of Fungal Infections in Critically Ill Patients
    Francisco Álvarez-Lerma, J. María Nicolás Arfelis, Juan Carlos Rodriguez-Borregan, Jazmín Díaz-Regañón, Marcío Borges-Sa, Fernando José García López, Alejandro Allepuz · 2005 · Journal of Chemotherapy
  46. Voriconazole: A Broad Spectrum Triazole for the Treatment of Serious and Invasive Fungal Infections
    Georg Maschmeyer, Antje Haas · 2006 · Future Microbiology
  47. Candidiasis
    José A. Vázquez, Jack D. Sobel · 2010 · Springer eBooks
  48. Invasive candidiasis in the ICU: evidence based and on the edge of evidence
    Eike Hollenbach · 2008 · Mycoses
  49. The use of caspofungin in HIV-infected individuals
    Laura Jane Waters, Mark Richard Nelson · 2007 · Expert Opinion on Investigational Drugs
  50. Antifúngicos de uso sistémico
    Carlos Lumbreras, Manuel Lizasoaín, José María Aguado · 2003 · Enfermedades Infecciosas y Microbiología Clínica
  51. Clinical pharmacology of antifungal agents in pediatric patients
    Christine C. Chiou, Thomas J. Walsh, Andreas H. Groll · 2007 · Expert Opinion on Pharmacotherapy
  52. Review of Pharmacologic Considerations in the Use of Azole Antifungals in Lung Transplant Recipients
    Megan E Klatt, Gregory A. Eschenauer · 2021 · Journal of Fungi
  53. Recomendaciones para el tratamiento de la infección fúngica invasiva. Infeccion fúngica invasiva por Candida spp.
    Joan Gavaldà, Isabel Ruíz-Camps · 2003 · Enfermedades Infecciosas y Microbiología Clínica
  54. Invasive Candidiasis
    Julia A Schroeder, Cameron M. Wilson, Peter G. Pappas · 2024 · Infectious Disease Clinics of North America
  55. Efficacy of caspofungin in invasive candidiasis and candidemia – de‐escalation strategy
    Christoph Lichtenstern, T. H. Nguyen, Peter Schemmer, Torsten Hoppe‐Tichy, Markus Alexander Weigand · 2008 · Mycoses
  56. Expanding the chemical space of 3(5)-functionalized 1,2,4-triazoles
    Dmytro M. Khomenko, Roman O. Doroshchuk, Yulia M. Ohorodnik, Hanna V. Ivanova, Borys V. Zakharchenko, Ilona V. Raspertova, Oleksandr V. Vashchenko, Alexey V. Dobrydnev, Oleksandr O. Grygorenko, Rostyslav D. Lampeka · 2022 · Chemistry of Heterocyclic Compounds
  57. New-generation triazole antifungal drugs: review of the Phase II and III trials
    Corrado Girmenia, Erica Finolezzi · 2011 · Clinical Investigation
  58. Antifungal therapy - state of the art at the beginning of the 21st century
    Annemarie Polak · 2003 · Birkhäuser Basel eBooks
  59. Successful Treatment of Refractory Majocchi’s Granuloma with Voriconazole and Review of Published Literature
    H. B. Liu, F. Liu, Qingtao Kong, Y. N. Shen, Guangxin Lv, W. D. Liu, Hong Sang · 2015 · Mycopathologia
  60. Esophageal perforation secondary to angio-invasive Candida glabrata following hemopoietic stem cell transplantation
    Huyen Anh Tran, Janette M. Vincent, Monica A. Slavin, A. Grigg · 2003 · Clinical Microbiology and Infection
  61. Invasive fungal infection--laboratory diagnosis and antifungal treatment.
    Pei Lan Shao, Li‐Min Huang, Po‐Ren Hsueh · 2006 · PubMed
  62. Safety, Efficacy, and Exposure–Response of Voriconazole in Pediatric Patients With Invasive Aspergillosis, Invasive Candidiasis or Esophageal Candidiasis
    Judith M. Martin, Mercedes Macías-Parra, Peter Múdrý, Umberto Conte, Jean Li Yan, Ping Liu, Maria Rita Capparella, Jalal A. Aram · 2016 · The Pediatric Infectious Disease Journal
  63. Voriconazole-Associated Myositis
    Victoria K. Shanmugam, Cal Matsumoto, Edward Pien, Jessica Rosen, Princy N. Kumar, Sean Whelton, Virginia D. Steen · 2009 · JCR Journal of Clinical Rheumatology
  64. Prophylaxis, empirical therapy, or pre-emptive therapy of fungal infections in immunocompromised patients: which is better for whom?
    Helen L. Leather, John R. Wingard · 2002 · Current Opinion in Infectious Diseases
  65. Voriconazole therapeutic drug monitoring: results of a prematurely discontinued randomized multicenter trial
    Dionysios Neofytos, Darin B. Ostrander, Shmuel Shoham, Michél Laverdière, J. Hiemenz, H. Nguyen, William A. Clarke, Lois Brass, N. Lu, Kieren A. Marr · 2015 · Transplant Infectious Disease
  66. Institutional Experience with Voriconazole Compared with Liposomal Amphotericin B as Empiric Therapy for Febrile Neutropenia
    Nadine Shehab, Daryl D. DePestel, Emily R. Mackler, Curtis D. Collins, Kathleen Welch, Harry Paul Erba · 2007 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
  67. Tratamiento de las infecciones fúngicas en pacientes con neoplasias hematológicas
    José Mensa, Rafael de la Cámara, Enric Carreras, Manuel Cuenca Estrella, José Ángel García Rodríguez, M Gobernado, Juan Picazo, José María Aguado, Miguel Ángel Sanz · 2009 · Medicina Clínica
  68. Drugs Active against Fungi, Pneumocystis, and Microsporidia
    John H. Rex, David A. Stevens · 2015 · Elsevier eBooks
  69. Breakthrough <i>Candida</i> Infections in Patients Receiving Voriconazole
    Gerzenshtein, Lana, Patel, Shilpa M, Scarsi, Kimberly K, Postelnick, Michael J, Flaherty, John P · 2005 · Annals of Pharmacotherapy
  70. Guías de práctica clínica para el manejo de la candidiasis: actualización del 2009, de la Infectious Diseases Society of America
    Peter G. Pappas, Carol A. Kauffman, David R. Andes, Daniel K. Benjamin, Thierry Calandra, John Ernest Edwards, Scott G. Filler, John F. Fisher, Bart Jan Kullberg, Luis L. Ostrosky-Zeichner et al. · 2009 · Clinical Infectious Diseases
  71. In vitro antifungal activity of different components of Centratherum anthelminticum and Ocimum sanctum seed oils and their synergism against oral pathogenic fungi
    Aparna H. Gopalkrishna, M. Seshagiri, Sunil Muddaiah, Raju Shashidara · 2016 · Journal of Dental Research Dental Clinics Dental Prospects
  72. Systemic Antifungal Agents
    John H. Rex, David A. Stevens · 2010 · Elsevier eBooks
  73. Role of Therapeutic Drug Monitoring of Voriconazole in the Treatment of Invasive Fungal Infections
    I fan Kuo, Mary H. H. Ensom · 2009 · The Canadian Journal of Hospital Pharmacy
  74. New and Emerging Antifungal Agents
    Marta Feldmesser · 2003 · American Journal of Respiratory Medicine
  75. Safety and Potential of Drug Interactions of Caspofungin and Voriconazole in Multimorbid Patients
    Vanessa Kulemann, Martin Bauer, Wolfgang Graninger, Christian Joukhadar · 2005 · Pharmacology
  76. Lack of hepato- and nephrotoxicity induced by antifungal drug voriconazole in laboratory rats
    Muhammad Nazrul Somchit, Jun Hung Chung, Azhar Yaacob, Zuraini Ahmad, Zainul A. Zakaria, Arifah Abdul Kadir · 2012 · Drug and Chemical Toxicology
  77. Determination of Voriconazole Concentrations in Serum by GC‐MS
    Alisha Smith, Van Leung‐Pineda · 2015 · Journal of Clinical Laboratory Analysis
  78. What’s new in antifungals?
    John M Valgus · 2003 · Current Infectious Disease Reports
  79. Anidulafungin: a novel echinocandin
    José A Vazquez · 2006 · Therapy
  80. New antifungal drugs and new clinical trials
    Corrado Girmenia, Pietro Martino · 2003 · Current Opinion in Oncology
  81. Long-term visual safety of voriconazole in adult patients with paracoccidioidomycosis
    Alan M. Laties, Frederick T. Fraunfelder, Konrad E. Tomaszewski, James Goodrich, Ana Tereza Ramos Moreira, Mário Teruo Sato, Flávio Queiroz‐Telles · 2010 · Clinical Therapeutics
  82. Systemic Antifungal Agents
    Shmuel Shoham, Andreas H. Groll, Vidmantas Petraitis, Thomas J. Walsh · 2016 · Elsevier eBooks
  83. JSMM Clinical Practice Guidelines for Diagnosis and Treatment of Invasive Candidiasis
    2013 · Medical Mycology Journal
  84. Anidulafungin and voriconazole in invasive fungal disease: pharmacological data and their use in combination
    Susanne Perkhofer, Cornelia Lass‐Flörl · 2009 · Expert Opinion on Investigational Drugs
  85. Neurologic Adverse Events Associated with Voriconazole Therapy: Report of Two Pediatric Cases
    Sevliya Öcal Demi̇r, Serkan Atıcı, Gülşen Akkoç, Nurhayat Yakut, Nilay Baş İkizoğlu, Ela Erdem Eralp, Ahmet Soysal, Mustafa Bakır · 2016 · Case Reports in Infectious Diseases
  86. British HIV Association guidelines on the management of opportunistic infection in people living with HIV : The clinical management of Candidiasis 2019
    David Harold Dockrell, Daire O’Shea, Jonathan D. Cartledge, AR Freedman · 2019 · HIV Medicine
  87. Voriconazole in the treatment of invasive fungal infections
    Simon Keady, Meera Thacker · 2005 · Intensive and Critical Care Nursing
  88. Antifungals: Drug Class, Mechanisms of Action, Pharmacokinetics/Pharmacodynamics, Drug-Drug Interactions, Toxicity, and Clinical Use
    Jeniel E. Nett, David R. Andes · 2014 · ASM Press eBooks
  89. Posaconazole for the Management of Mucosal Candidiasis
    José A. Vázquez · 2007 · Future Microbiology
  90. Clinical indications for newer antifungal agents
    Nina Naeger Murphy, James C. Pile · 2009 · Journal of Hospital Medicine
  91. Mucosal Candidiasis
    Sanjay G. Revankar, Jack D. Sobel · 2014 · ASM Press eBooks
  92. Evolving controversies and challenges in the management of opportunistic infections in HIV-seropositive individuals
    David Harold Dockrell, Simon Edwards, Martin Fisher, Ian G. Williams, Mark Richard Nelson · 2011 · Journal of Infection
  93. Liver cirrhosis as a predisposing factor for esophageal candidiasis
    Tzu‐Ming Ou, Hsin‐Hung Huang, Tsai‐Yuan Hsieh, Wei‐Kuo Chang, Heng-Cheng Chu, Chin‐Hui Hsu, Yu‐Lueng Shih, Tien‐Yu Huang, Peng‐Jen Chen, Hsuan‐Hwai Lin · 2014 · Advances in digestive medicine
  94. Gastrointestinal infections in the immunocompromised host
    Lori E. Fantry · 2003 · Current Opinion in Gastroenterology
  95. Voriconazol — Perspektiven und klinische Aspekte
    Markus Ruhnke · 2002 · Mycoses
  96. Nouveaux antifongiques : voriconazole et caspofungine
    B. Dupont · 2003 · Archives de Pédiatrie
  97. Treatment Options for Invasive Fungal Infections
    Elizabeth S. Dodds Ashley · 2006 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
  98. Systemic antifungal therapy for oesophageal candidiasis – systematic review and meta-analysis of randomized controlled trials
    Heyam Atamna Mwassi, Dafna Yahav, Gida Ayada, Sher Matsri, Ili Margalit, Liat Shargian, Jihad Bishara, Alaa Atamna · 2022 · International Journal of Antimicrobial Agents
  99. Opportunistic Infections in Aids Patients
    Nayara de Arruda Cáceres, Mateus Mazorra Coelho Vieira, Igor Fiorese Vieira, Vanessa Figuereido Monteleoni, Luiz Jorge Moreira Neto, Simone Martins Bonafé · 2015 · Archives of Medicine
  100. Pharmacokinetics, Safety and Efficacy of Voriconazole in Pediatric Patients: An Update
    Charalampos Dokos, Stephanie Pieper, Thomas Lehrnbecher, Andreas H. Groll · 2012 · Current Fungal Infection Reports